Cancers & treatments·Regimen libraryCurative

VAMP (vinblastine, doxorubicin, methotrexate, prednisone)

Checked 2026-09-09

Favourable early-stage Hodgkin lymphoma in children and adolescents (Stanford, St Jude and Dana-Farber), with low-dose involved-field radiotherapy

Also called VAMP.

One cycle

every 28 days × 4 · about 16 weeks in total

28-day cycle × 4 (about 16 weeks)IntravenousOral Daily oral course

Components

Drug	Dose	Route	Days
Vinblastine Vinca alkaloid (microtubule inhibitor)	6 mg/m²	IV	D1, 15
Doxorubicin Cytotoxic chemotherapy (anthracycline)	25 mg/m²	IV	D1, 15
Methotrexate Antifolate (DHFR inhibitor)	20 mg/m²	IV	D1, 15
Prednisone Glucocorticoid	40 mg/m² once daily	Oral	D1-14

Cycles

28-day cycle

Emetogenicity

Moderate (30-90%)

G-CSF

Not routine

Notes

Designed without alkylating agents, bleomycin or etoposide to spare fertility, lungs and second cancers in children with low-risk disease.
A later trial tested VAMP alone without radiotherapy for early responders.

Used in

Hodgkin lymphoma

Products

VinblastineDoxorubicinMethotrexatePrednisone

Source

Donaldson (Stanford, St Jude, Dana-Farber), JCO 2002: VAMP and low-dose involved-field radiation for favourable early-stage disease

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.